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RESEARCH ARTICLE Open Access
Serum thymidine kinase 1 activity as a
pharmacodynamic marker of cyclin-
dependent kinase 4/6 inhibition in patients
with early-stage breast cancer receiving
neoadjuvant palbociclib
Nusayba Bagegni1†, Shana Thomas1†, Ning Liu1†, Jingqin Luo1, Jeremy Hoog1, Donald W. Northfelt2,
Matthew P. Goetz3, Andres Forero4, Mattias Bergqvist5, Jakob Karen6, Magnus Neumüller5, Edward M. Suh5,
Zhanfang Guo1, Kiran Vij1, Souzan Sanati1, Matthew Ellis7 and Cynthia X. Ma1*
Abstract
Background: Thymidine kinase 1 (TK1) is a cell cycle-regulated enzyme with peak expression in the S phase during
DNA synthesis, and it is an attractive biomarker of cell proliferation. Serum TK1 activity has demonstrated prognostic
value in patients with early-stage breast cancer. Because cyclin-dependent kinase 4/6 (CDK4/6) inhibitors prevent
G1/S transition, we hypothesized that serum TK1 could be a biomarker for CDK4/6 inhibitors. We examined the
drug-induced change in serum TK1 as well as its correlation with change in tumor Ki-67 levels in patients enrolled
in the NeoPalAna trial (ClinicalTrials.gov identifier NCT01723774).
Methods: Patients with clinical stage II/III estrogen receptor-positive (ER+)/HER2-negative breast cancer enrolled in the
NeoPalAna trial received an initial 4 weeks of anastrozole, followed by palbociclib on cycle 1, day 1 (C1D1) for four 28-day
cycles, unless C1D15 tumor Ki-67 was > 10%, in which case patients went off study owing to inadequate response.
Surgery occurred following 3–5 weeks of washout from the last dose of palbociclib, except in eight patients
who received palbociclib (cycle 5) continuously until surgery. Serum TK1 activity was determined at baseline,
C1D1, C1D15, and time of surgery, and we found that it was correlated with tumor Ki-67 and TK1 messenger
RNA (mRNA) levels.
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Results: Despite a significant drop in tumor Ki-67 with anastrozole monotherapy, there was no statistically significant
change in TK1 activity. However, a striking reduction in TK1 activity was observed 2 weeks after initiation of palbociclib
(C1D15), which then rose significantly with palbociclib washout. At C1D15, TK1 activity was below the detection limit
(<20 DiviTum units per liter Du/L) in 92% of patients, indicating a profound effect of palbociclib. There was high
concordance, at 89.8% (95% CI: 79.2% - 96.2%), between changes in serum TK1 and tumor Ki-67 in the same direction
from C1D1 to C1D15 and from C1D15 to surgery time points. The sensitivity and specificity for the tumor Ki-67-based
response by palbociclib-induced decrease in serum TK1 were 94.1% (95% CI 86.2% - 100%) and 84% (95% CI 69.6% -98.
4%), respectively. The κ-statistic was 0.76 (p < 0.001) between TK1 and Ki-67, indicating substantial agreement.
Conclusions: Serum TK1 activity is a promising pharmacodynamic marker of palbociclib in ER+ breast cancer, and its
value in predicting response to CDK4/6 inhibitors warrants further investigation.
Trial registration: ClinicalTrials.gov, NCT01723774. Registered on 6 November 2012.
Keywords: Breast cancer, Thymidine kinase, Palbociclib, Anastrozole, Neoadjuvant, Biomarker
Background
Cytosolic thymidine kinase 1 (TK1) is a well-known cell
cycle-regulated enzyme important for nucleotide metabol-
ism during DNA synthesis [1]. TK1 catalyzes the conver-
sion of thymidine to deoxythymidine monophosphate,
which is further phosphorylated to di- and triphosphates
preceding its incorporation into DNA. The activity of TK1
is low or absent in resting cells, increasing in the G1/S tran-
sition and peaking in the S phase, and then disappearing
during mitosis [2–5]. Whereas serum TK1 activity is ele-
vated in cancer patients compared with healthy individuals
and prognostic in patients with breast and other cancers
[6–11], in very few studies have researchers evaluated the
utility of serum TK1 for monitoring responses to cancer
therapy.
Inhibitors against cyclin-dependent kinase 4/6 (CDK4/
6) are an important new class of agents with substantial
antitumor activity in patients with advanced hormone
receptor-positive (HR+) and human epidermal growth fac-
tor receptor 2-negative (HER2−) breast cancer [12–16].
These agents inhibit cell proliferation by activation of
retinoblastoma protein, which binds to E2F transcription
factors, leading to G0/G1 arrest [17, 18]. The preferential
activity of CDK4/6 inhibitors in luminal or HR+ disease is
due to the direct link between estrogen receptor (ER)
signaling and CDK4/6 activation, because cyclin D is a dir-
ect transcription target of ER and other mitogenic signals
associated with endocrine resistance [17, 18].
The potent antiproliferative effect of CDK4/6 inhibition
in ER+ breast cancer was demonstrated by tumor Ki-67
analysis in serial biopsies in the NeoPalAna trial (a phase II
trial of anastrozole and palbociclib, a CDK4/6 inhibitor, in
women with clinical stage II-III ER+/HER2− breast cancer),
in which the addition of palbociclib to anastrozole induced
complete cell cycle arrest (Ki-67 ≤ 2.7%) in 87% of patients,
as compared with 26% following single-agent anastrozole
treatment [19]. Because TK1 is a direct E2F transcription
target and is strictly cell cycle-regulated, we hypothesized
that changes in levels of TK1 activity before and after
administration of a CDK4/6 inhibitor would indicate suc-
cessful inhibition of CDK4/6, and also that serum TK1
activity could serve as a noninvasive surrogate marker of
antitumor activity of CDK4/6 inhibition. The serum sam-
ples collected before and after palbociclib in the NeoPalAna
trial provide an ideal sample set to test this hypothesis. The
objectives of this study were to compare TK1 activity in
serum collected before and after anastrozole and palboci-
clib, and to correlate serum TK1 activity with tumor Ki-
67 proliferation index and tumor TK1 mRNA levels in pa-
tients with early-stage ER+/HER2− breast cancer enrolled
in the NeoPalAna trial.
Methods
NeoPalAna trial patient population and study procedures
The NeoPalAna trial is a neoadjuvant phase II trial of
palbociclib, a CDK4/6 inhibitor, and anastrozole for clin-
ical stage II or III ER+/HER2− breast cancer, with the
primary endpoint of complete cell cycle arrest (Ki-67 ≤
2.7%) with the combination of anastrozole and palboci-
clib. The patient population and trial results were
described in our previous publication [19]. As illustrated
in Fig. 1, patients received anastrozole 1 mg orally daily
for one 28-day cycle (cycle 0, C0), followed by addition
of palbociclib 125 mg orally daily (days 1–21 of each 28-
day cycle) starting with cycle 1, day 1 (C1D1), for four
cycles, unless cycle 1, day 15 (C1D15), tumor Ki-67
was > 10%, in which case patients were taken off study
owing to inadequate response. Pre- and perimenopausal
women received goserelin 3.6 mg subcutaneously every
28 days. Anastrozole was continued until surgery, occur-
ring 3–5 weeks after palbociclib exposure, except in
eight patients for whom an additional 10–12 days of pal-
bociclib (cycle 5) was administered until surgery, follow-
ing the four cycles of combination therapy. Serial
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biopsies and blood collections were obtained at baseline
(prior to C0), C1D1, C1D15, and time of surgery. Tumor
biopsies were centrally analyzed for tumor Ki-67 level
using pathologist-guided image analysis [20]. In this trial,
we enrolled 50 patients (18 premenopausal and 32 post-
menopausal) (Table 1) with a median age of 58 (range
34–79) years, and demonstrated the potent antiprolifera-
tive effect of palbociclib in ER+/HER2− breast cancer,
even among patients resistant to anastrozole [19]. This
trial provided an appropriate sample set to correlate
serum TK1 activity with palbociclib treatment and
tumor Ki-67 response. TK mRNA levels were derived
from microarray analysis of tumor RNA (Agilent Gen-
omics, Santa Clara, CA, USA) [19]. Serum TK1 activ-
ity was determined at study enrollment (baseline,
C0D1), C1D1, C1D15, and time of surgery.
DiviTumTM assay for serum TK1 activity measurement
The DiviTumTM assay (Biovica International, Uppsala,
Sweden) was used for determination of serum enzymatic
activity of TK1 according to the manufacturer’s instruc-
tions (http://biovica.com/), as previously described [21].
When serum is mixed with the reaction mixture in a 96-
well enzyme-linked immunosorbent assay (ELISA) titer
plate, bromodeoxyuridine (BrdU) monophosphate is
generated by TK reaction, which is further phosphory-
lated to BrdU triphosphate and incorporated into a
DNA strand bound to the bottom of the well in the
microtiter plate. BrdU incorporation is then detected by
ELISA using an anti-BrdU monoclonal antibody conju-
gated to enzyme alkaline phosphatase and a chromo-
genic substrate, producing the optical density of the
color. The absorbance readings to DiviTum units per
liter (Du/L) are converted using the values from stan-
dards with known TK activity, with a working range
from 20 to 4000 Du/L. The analyses were performed at
the Biovica laboratory in Uppsala, Sweden, and investi-
gators were blinded to patient or tumor data.
In vitro cell culture experiment for effect of palbociclib on
intracellular TKA
The human cell line K562S (Sigma-Aldrich, St. Louis,
MO, USA) was seeded into T25 flasks (3 million cells/
flask) containing RPMI 1640 medium (Thermo Fisher
Scientific, Waltham, MA, USA) supplemented with 10%
FBS (Thermo Fisher Scientific), 100 U/ml penicillin, and
100 U/ml streptomycin (Thermo Fisher Scientific) and
treated with palbociclib (0.1 nM to 100 μM; Selleckchem,
Houston, TX, USA) for 6 h. Cells were then harvested for
determination of cell viability by trypan blue viability assay
or lysed for intracellular TK activity by DiviTum assay.
Statistical analysis
Box plots were generated to demonstrate tumor Ki-67
and TK1 mRNA by time point in all patients. Line plots
displayed the levels of serum TK1 activity and Ki-67 by
time point in patients in three tumor Ki-67 response cat-
egories. The Wilcoxon signed-rank test was used for
Anastrozole (A)
Palbociclib (P)











Fig. 1 Study schema for the NeoPalAna trial. Eligible patients with clinical stage II-III ER+/HER2− breast cancer received anastrozole monotherapy
for 28 days in cycle 0, followed by addition of palbociclib on cycle 1, day 1 (C1D1), for four 28-day cycles unless C1D15 Ki-67 was > 10%. Breast
surgery occurred after a washout of 3–5 weeks of palbociclib while the patient was continued on anastrozole, except for eight patients who also
received cycle 5 of palbociclib immediately prior to surgery. Serial tumor biopsies and blood collections occurred at baseline, C1D1, C1D15, and
time of surgery
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comparison between time points of serum TK1 activity,
tumor Ki-67 index, or tumor TK1 mRNA level. A value
of 20 Du/L was used to impute the measurements of
TK1 under the detection limit of 20 Du/L for statistical
analysis. The subject-level bivariate correlation coeffi-
cient (BCC) between serum TK1 and tumor Ki-67 (in
logarithmic scale) was calculated using the Bland-
Altman method [22], a meta-analysis approach, and the
bivariate linear mixed effects model [23]. The concord-
ance of serum TK1 activity change and tumor Ki-67
level change was evaluated by calculating the sensitivity
and specificity of decrease in TK1 for predicting de-
crease in tumor Ki-67 using data at C1D1, C1D15, and
time of definitive surgery, excluding the data of the eight
patients who were additionally treated with cycle 5.
Noncomparable data, such as undetectable TK1 activity
at both time points, was also excluded. All tests were
two-sided, and significance was set at a 5% α level. All
statistical analyses were performed using R version 3.3.2
software (R Foundation for Statistical Computing,
Vienna, Austria).
Results
Preclinical data indicating CDK4/6 inhibition reduces
intracellular TK1 activity in a dose-dependent manner
To assess the effect of CDK4/6 inhibition on intracellu-
lar TK1 activity, the human cell line K562S was cultured
in the presence of increasing concentrations of palboci-
clib (0.1 nM to 10 μM) for 6 h and harvested for Divi-
Tum analysis. Cell viability was also examined using
trypan blue at the same time. As shown in Fig. 2, TK1
activity was reduced in a linear and dose-dependent
manner in response to palbociclib with the short dur-
ation (6 h) of drug exposure, when the effect on cell via-
bility had not yet become obvious.
CDK4/6 inhibition reduced serum TK1 activity in
NeoPalAna trial
To determine whether serum TK1 activity could serve
as a surrogate marker for CDK4/6 inhibition and
tumor cell proliferation in patients receiving CDK4/6
inhibitors, we analyzed the sample set collected from
patients with clinical stage II-III ER+/HER2− breast
cancer who received neoadjuvant anastrozole and pal-
bociclib in the NeoPalAna trial [19]. As shown in
Fig. 3 and Table 2, there was no statistically signifi-
cant difference in TK1 activity between baseline and
C1D1 following 28 days of anastrozole monotherapy
(median serum TK activity was 46 versus 42.55 Du/L,
respectively; p = 0.52), despite a significant reduction
in tumor Ki-67 index, as well as, a reduction in
tumor TK mRNA level. In contrast, a striking decline
in TK activity was observed 2 weeks after initiation of
palbociclib (C1D15), with a median serum TK activity
of less than 20 Du/L, (p < 0.001); the serum TK activity
was below the detection limit of 20 Du/L in 92% (44 of
48) of patients. The remaining four participants had
serum TK activity of 24, 26, 26, and 58 Du/L, respect-
ively. This indicates a profound on-target inhibitory
effect induced by palbociclib. Following palbociclib
withdrawal, the median serum TK level increased sig-
nificantly from C1D15 to surgery (143.96 Du/L at sur-
gery), indicating recovery of CDK4/6 inhibition, with a
similar rebound in tumor Ki-67 observed at the time of
surgery. When an additional 10–12 days of palbociclib












































Cellular TK Activity 
Cell Viability
Fig. 2 Dose-dependent reduction of thymidine kinase 1 (TK1) activity in
response to cyclin-dependent kinase 4/6 inhibition in vitro. K562S cells
were treated for 6 h with palbociclib at the indicated concentrations,
followed by analysis of cell viability and TK1 activity. TK1 activity
was reduced in a linear and dose-dependent manner in response
to palbociclib prior to changes in cell viability. Du/L DiviTum units
per liter
Table 1 Patient characteristics (n = 50)
Characteristics Data
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the serum TK level remained suppressed at the time of
surgery at a level similar to C1D15 (median serum TK
activity < 20 Du/L; p = 0.7893). Collectively, these data
indicate that serum TK activity could serve as a phar-
macodynamic marker of CDK4/6 inhibition.
Serum TK activity in response to palbociclib by tumor Ki-
67 response category
To dissect the interaction between serum TK1 activity
in tumors with varying responses to palbociclib, we ana-
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Fig. 3 Box plots of serum thymidine kinase 1 (TK1), tumor Ki-67, and tumor TK1 messenger RNA (mRNA) levels by time point for patients enrolled
in the NeoPalAna trial. The comparison between time points was done using the Wilcoxon signed-rank test. Similar to tumor Ki-67, serum TK
activity was significantly lower on cycle 1, day 15 (C1D15), 2 weeks after adding palbociclib. However, unlike tumor Ki-67 and TK1 mRNA levels,
serum TK1 activity did not differ between baseline (C0D1) and cycle 1, day 1 (C1D1), with anastrozole alone. Similar to tumor Ki-67, a significant
rebound increase in serum TK1 level was observed at the time of surgery with palbociclib withdrawal, which was suppressed when an additional
cycle (cycle 5) of palbociclib was added before surgery. Tumor TK1 mRNA change at surgery time points did not reach statistical significance. *** p <
0.001, * p < 0.05
Table 2 Thymidine kinase 1 activity, Ki-67 and thymidine kinase messenger RNA over time




No. of participants Median (IQR) (%) No. of participants Median (IQR) (%) No. of
participants
Baseline (C0D1) 46 (25–73)
(9 cases < 20 Du/L)
48 24.34% (12.91–34.87%) 45 0.315 (−0.178 to 1.128%) 16
Cycle 1, day 1 (C1D1) 42.55 (29–94.6)
(8 cases < 20 Du/L)
49 5.37% (2.52–13.51%)a 45 −0.42 (−1.19 to 0.47%)b 33
Cycle 1, day 15 (C1D15) <20 (<20 to < 20)a
(44 cases < 20 Du/L)
48 0.78% (0.24–1%)a 45 0.98 (−1.89 to 0%)b 29
Surgery without C5 143.96 (90.9–306.4)a
(3 cases < 20 Du/L)
31 10.63% (4.59–23.67%)a 27 0.07 (−0.81 to 0.69%) 17
Surgery with C5 <20 (<20–21.5)
(3 cases < 20 Du/L)
6 0.52% (0.16–1.66%) 7 −0.35 (−1.98 to −0.11%) 6
Abbreviations: Du/L DiviTum units per liter, mRNA Messenger RNA, TK1 Thymidine kinase 1
C1D1: after 28 days of anastrozole (with goserelin if premenopausal) monotherapy
C1D15: 2 weeks following the addition of daily palbociclib to anastrozole on cycle 1, day 1
Surgery without C5: surgery occurred after four cycles (each cycle is 28 days) of palbociclib plus anastrozole, followed by a washout of palbociclib for 3–5 weeks
before surgery
Surgery with C5: cycle 5 (10–12 days of palbociclib) was administered immediately prior to surgery
a p < 0.001 compared with the preceding time point using the Wilcoxon signed-rank test (a value of 20 Du/L was used to impute the measurements of TK1 under
the detection limit of 20 Du/L)
b p < 0.05 compared with the preceding time point using the Wilcoxon signed-rank test (a value of 20 Du/L was used to impute the measurements of TK1 under
the detection limit of 20 Du/L)
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using the cut-off point of 2.7% (at which level complete
cell cycle arrest was defined): anastrozole-sensitive (C1D1
Ki-67 ≤ 2.7%), palbociclib-sensitive (C1D1 Ki-67 > 2.7%
but C1D15 Ki-67 ≤ 2.7%), and palbociclib-resistant
(C1D15 Ki-67 > 2.7%). As illustrated in Fig. 4, serum TK
levels were significantly reduced at C1D15 in both the
anastrozole-sensitive and palbociclib-sensitive groups,
followed by recovery at surgery due to palbociclib wash-
out. Neither serum TK1 activity nor tumor Ki-67 value
significantly changed in the palbociclib-resistant category.
Concordance in direction of changes between serum TK
activity and tumor Ki-67 in response to palbociclib
To assess palbociclib’s effect and evaluate concordance,
data were compared between C1D15 and C1D1, as well as
between C1D15 and surgery (no cycle 5), in individual pa-
tients. The overall concordance rate in the direction of
change between serum TK and tumor Ki-67 by palbociclib
was 89.8% (53 of 59 patients, 95% CI 79.2% - 96.2%)
(Table 3). The sensitivity and specificity of the decrease in
serum TK activity in predicting tumor Ki-67 reduction to
palbociclib were 94.1% (32 of 34, 95% CI 86.2% -100%),
and 84% (21 of 25, 95% CI 69.6% - 98.4%), respectively.
The κ-statistic was 0.76 (p < 0.001), indicating substantial
agreement between the two tests. The six discordant in-
stances between the effect of palbociclib on tumor Ki-67
and serum TK1 activity are shown in Fig. 5. Two of the
three discordant cases between C1D1 and C1D15 time
points had serum TK levels in the 20s (with 20 Du/L be-
ing the detection limit) at C1D1 (Fig. 5a and b), and one
of the three discordant cases between C1D15 and surgery
time points had a minimal change in both tumor Ki-67
and serum TK levels. This observation may have limited
the comparison between tumor Ki-67 and serum TK
activity changes.
The patient-level BCC between serum TK1 and tumor
Ki-67 was 0.46 by both the Bland-Altman method [22]
and a bivariate linear mixed effects model [23], indicat-
ing a medium correlation between the two. However, the
absolute value of serum TK1 activity at C1D15 did not
predict the persistent tumor proliferation assessed by Ki-
67 staining (Fig. 4 and Additional file 1: Table S1),
because all six cases had a serum TK1 activity below the
detection limit of 20 Du/L. Because of the significant
Anastrozole Sensitive (n=11)              Palbo Resistant (n=6)                Palbo Sensitive (n=26)
C0D1   C1D1     C1D15  Surgery C0D1   C1D1     C1D15  Surgery C0D1   C1D1     C1D15  Surgery










*p<0.05, ** p<0.01, ***p<0.001
Fig. 4 Serum thymidine kinase 1 (TK1) activity and tumor Ki-67 by time point and Ki-67 response category for individual patients. TK (top panel)
and Ki-67 (lower panel) levels in logarithmic scale over time for individual patients are shown in the line graphs. TK activity and Ki-67 from the same pa-
tient are denoted by the same line color. Palbociclib (Palbo) significantly reduced serum TK activity 2 weeks after initiation in the anastrozole-sensitive
or palbociclib-sensitive group by Ki-67. Palbo washout led to a significant increase in serum TK at the time of surgery. * p < 0.05, ** p <
0.01, *** p < 0.001. Filled triangles denote the average of TK or Ki-67 from different patients at the corresponding time points
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reduction in serum TK1 levels following anastrozole,
with serum TK1 levels < 20 Du/L in three patients and
only minimally elevated in three other patients (26, 29,
and 35 Du/L, respectively), we were unable to assess the
association between changes in serum TK1 activity and
Ki-67 between C1D1 and C1D15 time points in the
palbociclib-resistant category.
Discussion
Blood-based biomarkers are of great interest as noninva-
sive tools for assessing prognosis and in disease monitor-
ing. Circulating tumor cells, exosomes, circulating
tumor nucleic acids, and secreted proteins are the most
frequently investigated of these potential biomarkers
[24]. However, the clinical utility of such biomarkers is
often limited by unsatisfactory sensitivity, specificity, and
inter-laboratory reproducibility [25]. The DiviTum TK1
activity assay has been demonstrated to be a highly sen-
sitive and reliable measurement tool to measure cell
proliferation [6]. Because TK1 is a cell cycle-regulated
enzyme that plays a critical role in DNA synthesis, we
investigated whether serum TK1 activity could be used
as a surrogate marker of the antiproliferative effect of
palbociclib in patients with early-stage ER+/HER2−
breast cancer enrolled in the NeoPalAna trial (neoadju-
vant palbociclib and anastrozole).
This study demonstrates that serum TK1 activity was
significantly reduced after 2 weeks of treatment with pal-
bociclib, and that changes in serum TK1 significantly
correlated to changes in tumor Ki-67 proliferation index
and tumor TK1 mRNA levels. The overall concordance
rate in the direction of changes between serum TK and
tumor Ki-67 induced by palbociclib was 89.8% (53 of 59,
95% CI 79.2% -96.2%). A reduction in serum TK1
activity by palbociclib had a sensitivity of 94.1% (32 of
34, 95% CI 86.2% -100%) and a specificity of 84% (21 of
25, 95% CI 69.6% -98.4%) in predicting tumor Ki-67 re-
sponse in this patient population. To our knowledge,
this is the first study suggesting that serum TK1 activity
may be a promising noninvasive pharmacodynamic
marker of the antiproliferative effect of CDK4/6
inhibitors.
Uncontrolled cell proliferation is one of the key hall-
marks of cancer [26]. The value of TK1 as a cell prolifer-
ation marker was initially explored using IHC to study
human breast cancers [27]. Compared with the expres-
sion of proliferating cell nuclear antigen (PCNA),
Table 3 Concordance between changes in serum thymidine
kinase and changes in Ki-67 by palbociclib
Ki-67 ↓ (N) Ki-67 ↑ (N) Total (N)
TK ↓ (n) 32 4a 36
TK ↑ (n) 2a 21 23







Fig. 5 Serum thymidine kinase 1 (TK1) activity and tumor Ki-67 by time point for individual cases discordant in the direction of changes between
TK1 and Ki-67 levels. a and b Line graphs for TK1 activity and Ki-67 levels, respectively, for the three cases discordant when comparing data
between cycle 1, day 15 (C1D15), and cycle 1, day 1 (C1D1), time points. c and d Line graphs for TK1 activity and Ki-67 levels, respectively, for the
three cases discordant upon comparing data between C1D15 and surgery time points
Bagegni et al. Breast Cancer Research  (2017) 19:123 Page 7 of 11
although expression of both TK1 and PCNA was signifi-
cantly higher in malignant than in nonmalignant lesions,
only TK1 was associated with tumor stage or histological
grade [28], suggesting that it is a better proliferative
marker than PCNA. Serum TK1 was subsequently investi-
gated as a tumor marker using monoclonal or polyclonal
antibodies against TK1, demonstrating significantly higher
levels in preoperative breast cancer patients than in
healthy volunteers or patients with benign tumors or fol-
lowing curative surgery for breast cancer [29]. A separate
study demonstrated that higher serum TK1 levels
3 months after breast cancer surgery were associated with
increased risk of both locoregional and distant recurrence
[30]. These earlier studies led to further interest in devel-
oping serum TK1 assays and investigation into clinical ap-
plication. The innovative technology of the DiviTum assay
enables the measurement of serum TK1 activity with high
sensitivity and is compared favorably with other assay
platforms [6]. DiviTum serum TK1 activity has been ex-
plored as a prognostic marker in solid tumors, including
breast cancer [6–9, 21, 31]. Specifically, in a study of 368
women, including 149 healthy blood donors (control), 59
patients with benign breast disease (BBD), and 160 pa-
tients with primary breast cancer, serum TK1 activity was
significantly higher in those with invasive breast cancer or
with proliferative BBD than in those with nonproliferative
BBD and healthy control subjects [6]. Furthermore, serum
TK1 activity was significantly associated with tumor size,
lack of ER and PgR, tumor grade, and molecular subtype
[6]. Multivariate analyses adjusting for stage, grade, and
HR status demonstrated that serum TK1 was an inde-
pendent predictor of disease recurrence (p = 0.013) [6].
Additional studies demonstrated that TK1 activity was as-
sociated with progression-free survival and overall survival
in patients with advanced and metastatic breast cancer
[21]. However, in few studies only have researchers inves-
tigated the clinical utilityof serum TK1 activity in monitor-
ing therapeutic response to anti-neoplastic agents.
The particular interest in assessing serum TK1 activity
in response to CDK4/6 inhibitors stems from the known
cell cycle-inhibitory properties of these agents and their
importance in the management of patients with ad-
vanced HR+ breast cancer [18, 32]. Three CDK4/6
inhibitors, including palbociclib, ribociclib, and abemaci-
clib, are in clinical development for the treatment of
breast cancer and other solid malignancies. All three
CDK4/6 inhibitors have received U.S. Food and Drug
Administration approval for the treatment of advanced
HR+/HER2− breast cancer (Drugs@FDA; https://
www.accessdata.fda.gov/scripts/cder/daf/). However, des-
pite this success, especially in endocrine-naive disease,
resistance to CDK4/6 inhibitors eventually develops, and
a significant proportion of patients with HR+/HER2−
breast cancer fail to respond to CDK4/6 inhibitors in the
second-line setting (>30%) or beyond (>60%) following
progression on endocrine therapy [11, 13, 33]. The clin-
ical application of early response marker could lead to
beneficial changes in determining the optimal therapeutic
approach. Thus, the association between changes in
serum TK1 activity and tumor Ki-67 response to palbo-
ciclib observed in the NeoPalAna trial provides the
foundation for future exploration of the potential pre-
dictive nature of serum TK1 activity on response and
progression-free survival in patients receiving CDK4/6
inhibitors for metastatic disease.
Our study is limited by its small sample size. However,
the study is unique in its ability to obtain concurrent
tumor biopsies and serum sample collections for Ki-67
IHC and TK1 activity at serial time points in patients
with newly diagnosed, untreated HR+/HER2− breast
cancer. The initial treatment with anastrozole monother-
apy prior to the addition of palbociclib and the washout
of palbociclib prior to surgery allows for the evaluation
of dynamic changes in serum TK1 activity.
In this study, serum TK1 activity was not significantly
changed following treatment with 28 days of anastrozole
(Table 2). This is in spite of the statistically significant
reduction in tumor TK1 mRNA at C1D1 (Table 2). In
addition, a rise in serum TK1 activity at C1D1 was ob-
served in 3 of the 11 patients in the anastrozole-
sensitive group, although the changes were relatively
small (from baseline of < 20, 38, and 44 Du/L to 34, 60,
and 50 Du/L on C1D1, respectively) (Fig. 4). This was
unexpected because anastrozole inhibits CDK4/6 indir-
ectly through regulating cyclin D1 [34, 35]. As demon-
strated in our initial publication of the NeoPalAna trial,
anastrozole regulated the mRNA expression levels of a
wide range of genes, including those that were further
suppressed by the addition of palbociclib [19]. This is
supported by the significant reduction in tumor TK1
mRNA following anastrozole at C1D1 and a reduction
of serum TK1 activity in ~ 50% of patients. One possible
explanation for the lack of significant serum TK1
response following anastrozole is the relatively signifi-
cant contribution of serum TK1 activity from noncancer
cells in the early-stage breast cancer setting. In a study
in which investigators compared serum TK1 activity be-
tween healthy subjects and patients with breast cancer,
the median and IQR value for TK1 activity activity was
16 Du/L (IQR 9–33 Du/L) in the healthy blood donors
(n = 149) and moderately increased in patients with pri-
mary breast cancer prior to surgical exicision (n=160),
with median level of 37 Du/L (IQR 20–92 Du/L), re-
spectively. [6]. Although a statistically significant differ-
ence in serum TK1 activity was observed between the
two groups, overlapping values exist. As shown in
Table 2, the median baseline serum TK1 in patients en-
rolled in the NeoPalAna trial was 46 Du/L (IQR 25–
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73 Du/L), which is similar to that observed in the previ-
ous study [6]. Therefore, the antitumor effect of anastro-
zole may be difficult to translate into serum TK1
changes, because the antiproliferative effect of anastro-
zole is restricted to the estrogen-dependent breast can-
cer cells, whereas the nonmalignant cells are otherwise
not affected. This could particularly be the case in pa-
tients with lower baseline serum TK1 levels. The slight
or moderate rise of serum TK1 activity at C1D1 in those
three patients could also reflect fluctuations in individ-
uals because TK1 has a short half-life [4]. Therefore,
studies including patients with advanced disease in
which tumor cells contribute to the majority of the
serum TK1 activity are warranted.
Similarly, the discordance between serum TK1 and
tumor Ki-67 change in response to palbociclib, as well
as, the low serum TK1 activity despite persistent tumor
cell proliferation observed in patients in the palbociclib-
resistant category, could be explained by the inhibitory
effect of palbociclib on CDK4/6 in both cancer and non-
cancer cells in this setting of early-stage disease. How-
ever, we could not rule out the possibility that serum
TK1 activity is reduced only in CDK4/6-dependent can-
cer cells. Larger studies in patients with advanced dis-
ease will ultimately provide further insight and address
these possibilities.
Conclusions
Our study provides the first evidence that serum TK1 ac-
tivity as early as 2 weeks following CDK4/6 inhibitors is
highly correlated with tumor cell proliferation response in
patients with early-stage HR+ breast cancer. Future stud-
ies investigating the value of serum TK1 activity in moni-
toring treatment response and survival outcomes for
patients with metastatic breast cancers treated with endo-
crine therapy and CDK4/6 inhibitors are therefore
warranted.
Additional file
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